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Ketolides are promising new antimicrobials effective against a broad
range of Gram-positive pathogens, in part because of the low propen-
sity of these drugs to trigger the expression of resistance genes. A
natural ketolide pikromycin and a related compound methymycin are
produced by Streptomyces venezuelae strain ATCC 15439. The pro-
ducer avoids the inhibitory effects of its own antibiotics by expressing
two paralogous rRNA methylase genes pikR1 and pikR2 with seem-
ingly redundant functions. We show here that the PikR1 and PikR2
enzymes mono- and dimethylate, respectively, the N6 amino group
in 23S rRNA nucleotide A2058. PikR1 monomethylase is constitu-
tively expressed; it confers low resistance at low fitness cost and is
required for ketolide-induced activation of pikR2 to attain high-level
resistance. The regulatory mechanism controlling pikR2 expression
has been evolutionary optimized for preferential activation by ketolide
antibiotics. The resistancegenes and the inductionmechanism remain fully
functional when transferred to heterologous bacterial hosts. The antici-
pated wide use of ketolide antibiotics could promote horizontal transfer
of these highly efficient resistance genes to pathogens. Taken together,
these findings emphasized the need for surveillance of pikR1/pikR2-based
bacterial resistance and the preemptive development of drugs that can
remain effective against the ketolide-specific resistance mechanism.
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The prototypes of most of the clinically useful antibiotics, in-cluding the diverse group of protein synthesis inhibitors, have
been discovered among the secondary metabolites of bacterial
species. Antibiotic-producing bacteria have developed an array of
resistance genes to avoid committing suicide (1). The wide med-
ical use of antibiotics has created a strong selective pressure for
such resistance genes to transfer and integrate into the genomes
of bacterial pathogens, curbing the beneficial effects of the drugs
and shortening their clinical lifespan. Consequently, antibiotic
producers are not only our allies in providing useful drugs but also,
play an adversary role by facilitating the spread of resistance.
Macrolides are among the most medically successful antibiotics
originating from the secondary metabolites of actinomycetes. They
inhibit translation by binding in the nascent peptide exit tunnel
(NPET) close to the peptidyl transferase center (PTC) of the large
ribosomal subunit (2–4). The most common mechanism of mac-
rolide resistance involves dimethylation of an rRNA nucleotide in
the drug binding site (A2058 in the Escherichia coli 23S rRNA) by
Erm methyltransferases (5). In the absence of antibiotic, A2058
dimethylation is deleterious for the cell, because modification of a
residue in a functional site of the NPET distorts production of a
subset of proteins (6). Therefore, to reduce the fitness cost asso-
ciated with resistance, expression of the erm genes is often in-
ducible and activated only when antibiotic is present. Such
induction operates through antibiotic-controlled ribosome stalling
at an upstream leader ORF (5, 7).
Macrolide antibiotics are built on a 14- to 16-atom macrolactone
ring decorated with various side chains. The prototype 14-atom ring
macrolide erythromycin (ERY) and its second generation derivatives
carry cladinose at the C3-hydroxyl position of the ring and a desos-
amine sugar linked to the C5-hydroxyl group (Fig. 1B). In the newest
generation of drugs, the ketolides, the C3-cladinose is replaced with a
keto function. Ketolides are viewed as one of the most promising
classes of antibiotics presently under development and offer broad
medical application (8). The first medically useful ketolide teli-
thromycin (TEL) and newer ketolides currently in clinical trials show
dramatically improved antibacterial activity compared with earlier
generations of macrolides, and to a large extent, because of their
reduced propensity to activate inducible resistance genes (9, 10).
All of the clinically relevant ketolides are synthetic or semi-
synthetic derivatives of natural macrolides. The only naturally oc-
curring 14-atom macrolactone ring ketolide that is presently known
is pikromycin (PKM) (11) produced by Streptomyces venezuelae
(strain ATCC 15439) (Fig. 1). The biosynthesis pathway of PKM is
unique because of a modular polyketide synthesis skipping mech-
anism that can divert the pathway toward production of a second
macrolide molecule, methymycin (MTM), which has a smaller
macrolactone ring of 12 atoms (Fig. 1B) (12, 13). Although both
PKM andMTM possess antibacterial activity, their modes of binding
to the ribosome and their mechanisms of action remain unclear.
The modular polyketide synthesis genes pikAI-pikAV in the
biosynthetic cluster of S. venezuelae ATCC 15439 are preceded by
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two putative resistance genes, pikR1 and pikR2, arranged tail to tail
(Fig. 1A). The protein products PikR1 and PikR2 are 42% iden-
tical (Fig. S1) and show similarity to Erm-type rRNA methyl-
transferases (e.g., 30% and 28% identities with ErmE for PikR1
and PikR2, respectively) (14, 15). Given the significant fitness cost
associated with erm-based resistance (6), the duplication of PikR
enzymatic function in S. venezuelae is puzzling. Other than being
of general biological interest, the mechanism by which a natural
producer of ketolides attains resistance is of significant medical
importance. Not in the least, it can be envisioned that selective
pressure imposed by broad medical use of antibiotics could pro-
mote the transfer of natural resistance genes to pathogens. Un-
derstanding the function and regulation of pikR1/pikR2 and similar
genes would facilitate their surveillance and possibly, help curb
their dissemination. Study of pikR1/pikR2-like genes might, in turn,
stimulate preemptive development of drugs that retain antimicro-
bial activity against strains harboring these resistance mechanisms.
In this paper, we show that the pikR1 and pikR2 genes render
the ketolide-producing S. venezuelae cells resistant to PKM and
MTM as well as clinical ketolide antibiotics. Having determined
the target, the mode of action, and the regulation of these genes,
we reveal how S. venezuelae achieves ketolide resistance at a low
fitness cost by balancing the activities of PikR1 and PikR2 and
timing their expression. We present evidence that the expression
of pikR2 gene has been optimized through evolution to respond
to ketolide antibiotics. Finally, we show that transfer of pikR2 to
other bacteria renders them resistant to ketolides, and this effect
is accentuated in combination with pikR1. These findings illu-
minate resistance mechanisms that could potentially be acquired
by clinical pathogens on launching new ketolide antibiotics.
Results
pikR1 and pikR2 Confer Resistance to MTM and PKM.We first assessed
whether pikR1 and pikR2, which show similarity to macrolide re-
sistance erm genes (16), confer resistance to the natural ketolides
MTM and PKM produced by S. venezuelae. The pikR ORFs were
individually expressed from plasmids pPikR1 and pPikR2 (Table
S1) in an E. coli strain hypersusceptible to macrolides. Although
cells lacking these genes were completely inhibited by 4 μg/mL
MTM or 8 μg/mL PKM, expression of pikR1 or pikR2 rendered
E. coli resistant to >512 μg/mL either of the compounds. These
data indicate that pikR1 and pikR2 confer resistance to natural
ketolides and thus, have evolved or were acquired to protect
S. venezuelae from its endogenous antibiotics.
PikR1 and PikR2 Modify the Same 23S rRNA Nucleotide. The presence
of two resistance genes of potentially similar function may suggest
that one of them is redundant, prompting us to dissect their indi-
vidual functions. The binding sites of MTM and PKM in the bac-
terial ribosome have not been biochemically defined previously.
However, structural evidence from the Deinococcus radiodurans
large ribosomal subunit suggests that MTM binds in the PTC (17)
rather than in the NPET, where all conventional macrolides and
ketolides bind (2–4). Therefore, the site of action and the nature of
the modifications introduced by PikR1 and PikR2 could not be
predicted with any certainty. The majority of the investigated Erm-
type enzymes confer resistance to macrolides by dimethylating the
exocyclic amine of A2058 in the 23S rRNA (E. coli numbering
throughout) (5). A2058 dimethylation (but not monomethylation)
stalls the progress of reverse transcriptase (RT) on the RNA tem-
plate and is readily detected by primer extension. A strong band
corresponding to RT pausing at A2058 on rRNA extracted from
E. coli cells expressing PikR2 indicated that it probably dimethylates
this nucleotide (Fig. 2A and Fig. S2A). In contrast, under the stan-
dard primer extension conditions, no RT stop was detected at either
A2058 or any other site within the PTC and the NPET on rRNA
from cells with pPikR1 (Fig. 2A). However, when we optimized
primer extension conditions for detecting N6 monomethylation of
adenosine (Materials andMethods and Fig. 2B), RT pausing at A2058
was observed on rRNA from cells expressing PikR1 (Fig. 2B, lane 2),
supporting the hypothesis that PikR1 monomethylates A2058.
The nature of the reactions catalyzed by PikR1 and PikR2 was
corroborated by MS. A 50-nt-long 23S rRNA fragment encom-
passing A2058 was isolated from rRNA extracted from E. coli cells
expressing PikR1 or PikR2 and subjected to RNaseA digestion and
MALDI-TOF analysis. In the PikR1 sample, the peak corre-
sponding to the unmodified RNA fragment GGA2058AAGAC (m/z
2,675) was almost absent, and a new peak at m/z 2,689 appeared
(Fig. 2C), indicating that a methyl group had been added. In the
corresponding 23S rRNA fragment from the PikR2 sample, the
unmethylated RNA peak was also absent and replaced by a peak at
m/z 2,703 showing the addition of two methyl groups (Fig. 2D).
Combined with the results of primer extension analysis, the MS
data showed that PikR1 and PikR2 target the same rRNA nucle-
otide but generate two different products: PikR1 monomethylates
A2058, whereas PikR2 dimethylates this nucleotide.
pikR1 Is Constitutively Expressed in the Native Host, Whereas pikR2 Is
Activated only When Antibiotics Are Produced.Why does a ketolide
producer that is equipped with the A2058 dimethyltransferase
gene pikR2 also need the pikR1 gene, which has a product that
merely monomethylates the same nucleotide? To address this
question, we examined the regulation of expression of pikR1 and
Fig. 1. S. venezuelae pikR resistance genes and ketolide antibiotics. (A) The
structure of theMTM/PKMbiosynthetic gene cluster in S. venezuelaeATCC 15439.
The polyketide synthase (pikA) and desosamine biosynthesis (des) gene operons
along with the pikC and pikD genes are required for production of the active
MTM and PKM antibiotics. The putative resistance genes pikR1 and pikR2 precede
the MTM/PKM biosynthesis operon. (B) Structures of the natural antibiotics MTM
and PKM produced by S. venezuelae ATCC 15439, the semisynthetic clinical
ketolide TEL, and the C3-cladinose containing macrolide ERY. The dotted box in
the TEL structure highlights the keto group, which replaces the cladinose sugar.
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pikR2 in S. venezuelae. When production of antibiotics was
inactivated by deletion of either the pikAI-pikAIV genes (ΔpikA)
or the desI gene (ΔdesI) in the biosynthetic operon (leaving the
pikR1 and pikR2 resistance genes intact) (Table S2), A2058 was
found to be fully monomethylated (Fig. 3 and Fig. S2B), but
there was essentially no dimethylation of this residue (Fig. 3 A,
D, and E). This result indicated that pikR1 is constitutively
expressed, whereas pikR2 remains inactive when no antibiotic is
produced. In contrast, in the antibiotic-producing WT S. venezuelae
ATCC 15439, a significant fraction (∼30%) of A2058 was shown by
primer extension to be converted to m2
6A (Fig. 3A and Fig. S3), an
observation confirmed by MS (Fig. 3C). Thus, pikR2 is activated
only when MTM and/or PKM are present in the cell. Because
dimethylation of A2058 is known to reduce cell fitness (6), the
inducible nature of pikR2 is consistent with an evolutionary adap-
tation by the antibiotic-producing host to achieve secure protection
against endogenously produced ketolides while maintaining a low
fitness cost for this service.
Expression of pikR2 Is Activated in the Natural Host by Clinically
Relevant Ketolides. Induction of pikR2 by ketolides of its native
host suggested that the gene could also be activated by medically
relevant ketolides. We tested whether preincubation with the
clinical ketolide TEL could induce pikR2 expression in S. venezuelae.
Derivative strains containing only pikR1 (DHS328) or only pikR2
(DHS330) or lacking both genes (DHS332; designated here as
R1, R2, or Δ, respectively) were prepared from the ΔpikA strain
(DHS2001; designated here as WT*) (18). Without preincubation,
the WT* and R1 cells showed an intermediate level of resistance to
TEL [minimal inhibitory concentration (MIC) = 8 μg/mL], whereas
R2 and Δ were highly sensitive (MIC = 0.25 μg/mL). Preincubation
of the WT* and R2 strains with TEL concentrations of one-fourth
MICs raised their respective resistance levels 8- and 64-fold, re-
spectively (Table 1). The higher resistance of the WT* and R2 cells
on exposure to TEL correlated with increased modification of nu-
cleotide A2058 (Fig. S4). The microbiological and biochemical data
thus show that, although constitutive expression of pikR1 provides
some protection from the clinical ketolide TEL, resistance is dra-
matically increased by drug-mediated activation of pikR2.
Molecular Mechanism of pikR2 Induction.Macrolide resistance genes
are activated by programmed ribosome stalling at the upstream
leader ORFs (5, 19). Many of the resistance genes are induced
exclusively or preferentially by cladinose-containing macrolides,
whereas ketolides are poor inducers (10, 20). Indeed, ketolides
owe their high activity against many clinical isolates to their low
propensity for activation of inducible resistance genes.
We were interested in elucidating the molecular mechanism of
ketolide-dependent induction of the pikR2 gene. Examination of
the pikR2 upstream regions revealed the presence of a 16-codon
ORF (pikR2L) 157 bp upstream of pikR2 (Fig. 4A). The role of
pikR2L in ketolide-mediated inducibility was investigated using a
plasmid construct containing the pikR2L ORF, the intergenic re-
gion, and the first five codons of pikR2 fused to the lacZα reporter
gene (Fig. 4B). An E. coli Ptac promoter drives transcription of the
reporter system. Induction of the pikR2-lacZα chimera was tested
in E. coli by a disk diffusion assay (21). Natural and semisynthetic
clinical ketolide antibiotics but notably, not the cladinose-con-
taining macrolide ERY activated expression of the pikR2L-based
reporter system (Fig. 4B). These data showed that ketolide-spe-
cific induction of pikR2 occurs at the level of translation and is
likely controlled by the upstream leader ORF.
The mechanism of translational induction was investigated in a cell-
free transcription–translation system using a primer extension in-
hibition assay (toe printing) (22, 23) to test for ketolide- and macro-
lide-induced ribosome stalling on the pikR2LmRNA. BothMTMand
PKM induced strong translation arrest at the Leu13 codon of pikR2L
Fig. 2. PikR1 and PikR2 RNA methyltransferases target A2058 in the 23S
rRNA. (A) Primer extension analysis of m2
6A modification of rRNA extracted
from WT E. coli cells (W; lane 3) or those constitutively expressing pikR1 (R1;
lane 2) and pikR2 (R2; lane 1) genes. Sequencing lanes are marked C, U, A, G.
Full gels are shown in Fig. S2A. (B) Primer extension analysis of the same samples as
in A but carried out under conditions optimized for detection of m6Amodification
(Materials and Methods). The E. coli ΔrlmJ mutant, which lacks the native m6
modification of A2030 (33), was used as a control (Δ; lane 4). (C and D) MALDI-TOF
analysis of the RNaseA-generated 23S rRNA fragment encompassing nucleotide
A2058. rRNA samples were prepared from cells expressing (C) PikR1 or (D) PikR2.
Fig. 3. Expression of pikR2 in S. venezuelae is activated during antibiotic
production. (A and B) Primer extension analysis of rRNA extracted from WT
S. venezuelae ATCC 15439 carried under conditions specific for detection of
(A) m2
6A or (B) m2
6A andm6Amodification. Full gels are shown in Fig. S2B. RNA
was extracted from WT cells or mutants unable to produce active antibiotics
because of deletion of the pikAI-pikAIV (ΔpikA) or desI (ΔdesI) genes. Sequencing
lanes in A and B are marked C, U, A, G. (C–E) MALDI-TOF analysis of 23S rRNA
fragments from theWT or the ΔpikA and Δδ«σI KOmutants of S. venezuelae; the
fragments were generated with RNaseA and encompass nucleotide A2058.
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(Fig. 4C, lanes 2 and 3). Unexpectedly, the clinical ketolide TEL was
even more potent in arresting the ribosome at the Leu13 codon (Fig.
4C, lane 4). In contrast, consistent with the lack of in vivo induction of
the pikR2L reporter system by ERY (Fig. 4B), this macrolide failed to
induce ribosome stalling (Fig. 4C, lane 5). Taken together, these re-
sults suggest that pikR2 has been evolutionarily optimized for specific
activation by natural ketolide antibiotics and that semisynthetic clinical
ketolides can serve as even more potent inducers.
Computational analysis shows that a stable stem-loop configuration
of mRNA in the pikR2L-pikR2 intergenic region may sequester the
pikR2 ribosome binding site (Fig. S5A). Ketolide-induced ribosome
stalling at the Leu13 codon of pikR2L would destabilize the proximal
mRNA stem and promote an alternative conformation, in which the
initiation region of pikR2 is accessible for translation (Fig. S5B).
Inducible Expression of pikR2 Alone or Combined with pikR1 Confers a
High Level of Ketolide Resistance in a Clinically Relevant Host. After es-
tablishing that the natural resistance mechanisms conferred by pikR1
and pikR2 in the Streptomyces ketolide producer remain operational
on transfer to E. coli, we extended the investigation to a heterologous
Gram-positive model, because Gram-positive pathogens are the pri-
mary clinical targets of macrolides and ketolides. Mycobacterium tu-
berculosis is the etiological agent of tuberculosis and considered a
possible target for ketolide therapy (24). We constructed strains of
Mycobacterium smegmatis, a laboratory model of the pathogenic
mycobacteria, which carried either the pikR2 gene controlled by its
regulatory region or the entire pikR1-pikR2 cluster on a plasmid
(Fig. 1A). The presence of pikR2 alone elevated the resistance of
M. smegmatis to clinical ketolides by 16- to 32-fold (Table 2). The
combination of pikR1 and pikR2 conferred a much higher level of
resistance (exceeding 1mg/mL for TEL). Constitutive monomethylation
of A2058 by PikR1 most likely facilitates continued ribosome activity
and expression of pikR2 on abrupt exposure of the cells to high con-
centrations of ketolides. WhenM. smegmatis cells with pikR2 or pikR1-
pikR2 were preincubated with subinhibitory concentrations of TEL,
resistance reached even higher levels, exceeding those of the control
cells by several hundredfold (Table 2). Thus, the resistance genes
originating in the producer of natural ketolides can render heterologous
bacteria resistant to high concentrations of clinical ketolide antibiotics.
Discussion
In this paper, we present evidence that the genes pikR1 and pikR2
have been evolutionary optimized to confer resistance to ketolide
antibiotics. These genes not only render S. venezuelae ATCC 15439
resistant to its endogenously produced ketolides but also, confer
appreciable resistance to clinical ketolides. The resistance conferred
by pikR1 and pikR2 can be transferred to heterologous Gram-neg-
ative and -positive hosts. We further show that the fitness cost of
resistance is economized by the ketolide-inducible expression of
pikR2. Taking these factors into account, acquisition of the pikR1
and pikR2 genes is expected to confer a marked selective advantage
on bacteria undergoing repeated exposure to ketolides, which could
promote the transfer of these genes to pathogens when ketolides
become more widely used in a clinical setting.
Our studies provide insights into the important question of why
S. venezuelae, the producer of the natural ketolides MTM and PKM,
maintains two resistance genes with seemingly overlapping functions.
The constitutively expressed PikR1 monomethylates 23S rRNA nucle-
otide A2058 located at the site of ketolide action, and this modification
confers an intermediate level of resistance. Higher levels of resistance
are attained with the inducible PikR2, which adds a second methyl
group to the same nucleotide. The combined action of two differen-
tially expressed genes ensures active protein synthesis in the ketolide-
producing cells across a broad range of the inhibitors concentrations.
The inducibility of pikR2 is significant for the operation of the
resistance mechanism. Although dimethylation of A2058, at least
in Staphylococcus aureus, is known to significantly reduce cell fit-
ness (6), monomethylation of the same nucleotide seems to have
little, if any, effect on S. venezuelae fitness (Fig. S6). Thus, with a
minimal toll in fitness cost for the constitutive PikR1 mono-
methyltransferase, S. venezuelae easily tolerates low concentrations
of MTM and/or PKM. However, when S. venezuelae augments its
production of these drugs, activation of the more costly PikR2
enzyme is required, resulting in A2058 dimethylation and higher
resistance levels. Producers of other natural antibiotics, which carry
more than one resistance gene, may use a similar strategy for
achieving the cost-effective protection from inhibitors (25).
In contrast to other inducible erm genes, which respond pri-
marily to macrolides bearing a C3-cladinose, the regulation of
pikR2 has been evolutionary optimized for specific activation by
ketolides (Fig. 4). Ketolide-specific pikR2 induction is most likely
controlled by programmed translation arrest within the pikR2L
leader ORF. Cladinose-containing macrolides are prone to pro-
moting early peptidyl-tRNA drop off occurring within the first 6–10
codons (26). Consistently, the sites of programmed macrolide-
dependent translation arrest within the leader ORFs of the resistant
genes are located within the ORF’s first 10 codons, so that the
drug-bound ribosome is able to reach the arrest site without pre-
maturely dissociating from the mRNA (5, 19, 23, 27). Ribosomes
translating pikR2L have to travel slightly farther and polymerize 13
amino acids before reaching the stalling codon. Because ketolides
are less prone to promoting peptidyl-tRNA drop off (28), it is
easier for ketolide-bound ribosomes than for ERY-bound ribo-
somes to polymerize the 13-aa-long nascent PikR2L chain. Indeed,
the ERY-bound ribosome does not reach the stalling site (Fig. 4
and Fig. S5) and thus, fails to trigger pikR2 expression. Ketolide-
induced stalling in the pikR2L ORF occurs within the motif RLR,
which represents one of the most problematic sequences for
translation by ketolide-bound ribosomes (28, 29). We note that a
short ORF is also found in front of the constitutively expressed
Table 1. MIC (micrograms per milliliter) of TEL or chloramphenicol for S. venezuelae ΔpikA
strains containing different pikR resistance genes
Strain†
Antibiotics
TEL Chloramphenicol
Preincubation
Fold change
Preincubation
Fold changeNo Yes‡ No Yes‡
WT* 8 64 8 8 8 1
Δ 0.25 0.25 1 8 8 1
R1 8 16 2 8 8 1
R2 0.25 16 64 8 8 1
†The ΔpikA strain, which contained both pikR1 and pikR2 resistance genes but was unable to produce anti-
biotics (DHS2001), was designated WT* control. Formal names of the other strains are DHS332 (Δ), DHGS328
(R1), and DHS330 (R2).
‡Cells were grown for 8 h in LB supplemented with one-fourth MIC of TEL (0.0625 μg/mL for Δ and R2 strains or
2 μg/mL for WT* and R1 strains) before MIC testing.
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pikR1 gene (Fig. S7A), although this ORF does not promote
macrolide- or ketolide-dependent stalling (Fig. S7B) and thus,
seems to play no role in the expression of pikR1.
The properties and regulation of the pikR1 and pikR2 genes are
principally important for tolerating the broad range of inhibitor
concentrations experienced by S. venezuelae. Constitutive mono-
methylation of A2058 by PikR1 renders ribosomes moderately re-
sistant to ketolides, affording protection to S. venezuelae at the early
stages of antibiotic production. Monomethylation of A2058 is a
critical step toward acquisition of a high level of resistance, facili-
tating efficient translation of pikR2, despite the presence of a keto-
lide inhibitor. Indeed, on abrupt exposure of the S. venezuelae pikR1-
null mutant (ΔpikR1) to TEL, the lone pikR2 gene was unable to
provide any significant protection (Table 1), but when both pikR
genes were present and cells were preincubated with low ketolide
concentrations (mimicking the onset of antibiotic production), a high
level of resistance was achieved. In the absence of pikR1, the re-
sistance of S. venezuelae to TEL afforded by pikR2 alone, even on
preincubation with the antibiotic, was no higher than that provided
by the constitutively expressed monomethylase (Table 1). This
intermediate level of resistance may be caused by either dimethy-
lation of only a small fraction of ribosomes or mixed mono- and
dimethylations, because Erm dimethyltransferases are known to add
two methyl groups to A2058 in two consecutive reactions (30).
The synergy between the pikR1 and pikR2 genes was observed to
an even greater extent inM. smegmatis, which was used to model the
expression of the pikR genes in clinical pathogens. Here, the pikR2
gene alone conferred considerable resistance to clinical ketolides.
However, it was the simultaneous presence of both pikR1 and pikR2
genes that provided the highest resistance (Table 2). The resistance
to TEL afforded by pikR1 and pikR2 in M. smegmatis was signifi-
cantly higher than in S. venezuelae. Factors that could contribute to
this effect include the increased dosage of the resistance genes in-
troduced into mycobacteria on a plasmid, the slower subunit as-
sembly resulting in a higher proportion of methylated rRNA, or the
lower affinity of the antibiotic for modified mycobacterial ribosomes.
The inducibility of pikR2, which lowers the fitness cost of the two-
gene resistance mechanism, may facilitate not only its acquisition by
a new host through horizontal gene transfer but also, its mainte-
nance on discontinuation of the antibiotic treatment. Horizontal
transfer of the pikR1/pikR2 gene pair may be further facilitated by
their close physical proximity in the S. venezuelae chromosome (Fig.
1A). Despite the high GC content of pikR1 and pikR2, our results
strongly suggest that their transfer into at least some clinical strains
would render the strains highly resistant to ketolide therapy. These
findings, thus, provide additional justification for renewed drug
discovery efforts to identify novel antibiotics capable of overcoming
protection rendered by natural resistance genes.
Materials and Methods
For isolation of the total RNA from S. venezuelae, cells were grown overnight in
SGGP media, then diluted 1:100 in SCM media (31), and grown for 5 d at 30 °C
with constant shaking. Cells were pelleted from 5-mL cultures, resuspended in
1mL Tris-EDTA (TE) buffer (10mMTris·HCl, pH 8.0, 1mMEDTA) containing 5mg/mL
lysozyme, incubated for 10 min at room temperature, and then, shaken for
10min in theMinibead Breaker (Biospec Products) with 50 μL glass beads (particle
size ≤106 μm; Sigma-Aldrich). Total RNA was isolated using the RNeasy Maxi
Kit (Qiagen).
The RNeasy Plus Mini Kit was used to prepare total RNA from exponentially
growing E. coli following the standard manufacturer’s protocol. Primer extension
analysis under the standard conditions suitable for detection of adenine N6
dimethylation was carried out as previously described (21). In experiments where
Fig. 4. The pikR2 regulatory region controls the inducible expression of the
pikR2 resistance gene. (A) The putative leader ORF pikR2L precedes the pikR2
resistance gene. The nucleotide sequence of the ORF and the amino acid sequence
of the encoded leader peptide are shown. (B) Antibiotic disk diffusion assay re-
veals inducibility of pikR2 in E. coli. In the reporter construct in E. coli cells, the
pikR2 regulatory region controls expression of the lacZα reporter. The antibiotic
disks contained TEL, MTM, PKM, ERY, or chloramphenicol (CHL). The clear areas
around the disks contain antibiotic concentrations that inhibited cell growth. Blue
halos around the ketolide-containing disks indicate drug-dependent induction of
the reporter. (C, Upper) Toe-printing analysis shows ketolide-induced ribosome
stalling at the Leu13 codon of the pikR2L ORF. The band of the ribosomes stalled
by the control antibiotic thiostrepton (THS) at the initiation codon is indicated by
black arrows. The ribosomes arrestedwith the Leu13 codon in their P site are shown
by the red arrows. The ribosomes that reached the pikR2L 13th codon but failed to
arrest translation were captured at the next Arg14 codon (blue arrows) because of
the depletion of Ile-tRNA from the translation reaction by the presence of the
Ile-tRNA synthetase inhibitor,mupirocin. The stop codon or theORF is indicatedwith
an asterisk. (C, Lower) Stalling efficiency calculated from the ratios of the intensity of
the bands representing ketolide-dependent arrest (codon 13) vs. read through (co-
don 14). Error bars indicate data spreads in two independent experiments.
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detection of N6 monomethylation was required, the concentration of dTTP was
reduced from 1 to 0.01 mM with extension for 15 min at 37 °C instead of the
standard 30min at 42 °C. Primers L2180, L2563, and L2667 (Table S3) were used to
examine domain V of 23S rRNA of E. coli. Primer L2405-R was used to check the
modification status of A2058 in 23S rRNA of S. venezuelae.
Toe printing was carried out as described previously (23). The status of
rRNA modification in E. coli and S. venezuelae was analyzed using the ap-
proach described in ref. 32.
Other experimental details are provided in SI Materials and Methods.
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Table 2. MIC (micrograms per milliliter) of clinically relevant ketolides for M. smegmatis
harboring the pikR2 gene alone or the combination of pikR1 and pikR2 genes
Plasmid
TEL SOL CET
Preincubation Preincubation Preincubation
No Yes* No Yes* No Yes*
pMIP12 (vector) 2 2 1 1 1 2
pMR2 64 2,048 16 1,024 32 512
pMR1R2 1,024 2,048 256 1,024 256 512
Antibiotics used were TEL, solithromycin (SOL), and cethromycin (CET). TheM. smegmatis strain used in MIC
testing was a derivative of the strain mc2155, in which the endogenous macrolide resistance gene erm38 was
inactivated by allelic exchange (34).
*Cells were grown for 72 h in the medium supplemented with one-eighth MIC of TEL (0.25 μg/mL for cells
transformed with the empty vector, 8 μg/mL for cells transformed with pMR2, or 128 μg/mL for cells trans-
formed with pMR1R2) before MIC testing.
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